Exploration on the Mechanism of Fufei Jiedu Prescription in the Treatment of Lung Adenocarcinoma based on Network Pharmacology and Molecular Docking
DOI:
https://doi.org/10.53469/jcmp.2024.06(12).43Keywords:
Fufei Jiedu prescription, Lung adenocarcinoma, Network pharmacology, Molecular dockingsAbstract
Objective: This investigation aims to elucidate the mechanism of action underlying the Fufei Jiedu formula in the treatment of lung adenocarcinoma by employing network pharmacology techniques and molecular docking strategies. Methods: The TCMSP, HERB, BATMAN, ETCM databases and analysis platforms were utilized to identify active ingredients and potential targets. The genes associated with lung adenocarcinoma were searched in the OpenTargets, DrugBank, and GeneCards databases to identify the intersection targets of the FuFei JieDu detoxification and lung adenocarcinoma. Subsequently, a FuFei JieDu detoxification-component-target-lung adenocarcinoma network model map was created using Cytoscape3.9.1 software. Additionally, The STRING database was utilized to construct a protein-protein interaction (PPI) network map in order to identify key targets. The GO function and KEGG pathway enrichment analyses were conducted to explore the potential mechanisms of drug action on the disease. Finally, molecular docking was conducted to confirm the binding affinity of key active components and core targets using AutoDock Tools software. Results: The research identifying 99 active compounds and their 582 associated targets connected to lung adenocarcinoma. 121 intersection targets were selected, including 5 chemical compound that serve as the material basis for the treatment of lung adenocarcinoma, luteolin, wogonin, baicalein and kaempferol. After analyzing the PPI network map, core targets such as TP53, AKT1, STAT3, EGFR, MYC, BCL2, and CTNNB1 were identified. The GO and KEGG enrichment analysis revealed that121 genes were primarily enriched in biological processes such as programmed cell death, immune regulation, and oxidative stress, as well as signaling pathways including PI3K/Akt, AGE/RAGE, TNF, and PDL-1pathway. The outcomes of the molecular docking studies uncovered these associations, compounds such as EGFR, CTNNB1, and AKT1 had good affinity with target molecules like quercetin, Calycosin, baicalin, β-sitosterol, and Delta-D. Conclusion: A variety of components such as quercetin, Calycosin, baicalin, β-sitosterol, and Delta-D in the Fufei Jiedu prescription may participate in the regulation of multiple pathways such asPI3K/Akt, AGE/RAGE, TNF, and PDL-1 pathway by acting on EGFR, CTNNB1, AKT1 and other targets to inhibit the proliferation, invasion and metastasis of lung adenocarcinoma, and play a synergistic anti-tumor effect.
References
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263.
heng RS, Chen R, Han BF, et al. [Cancer incidence and mortality in China, 2022]. Zhonghua Zhong Liu Za Zhi. 2024 Mar 23;46(3):221-231.
H. M. Abdelaziz, M. Gaber, M. M. Abd-Elwakil, et al. Elzoghby Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates J. Control Release, 269 (2018), pp. 374-392
Roberto Ruiz-Cordero, Walter Patrick Devine, Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer, Surgical Pathology Clinics, Volume 13, Issue 1, 2020, Pages 17-33
Hinshaw DC, Shevde LA. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019 Sep 15; 79(18): 4557-4566.
Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study [J]. J Clin Oncol, 2018, 36(17): 1675-1684.
Wang Yuanchun. Study of Clinical and Metabolomics on the Treatment of Non-small Cell Lung Cancer Based on Pathogenesis Theory of Cancerous toxin[D]. Nanjing University of Chinese Medicine, 2022.
Wang Xiaoyu. Meta-analysis and Network Pharmacology Study of Guipi Decoction in the treatment of Post-Stroke Depression[D]. Shaanxi University of Chinese Medicine, 2022.
ZHANG Xiaowen, LIU Aimin, ZHAO Jingjing, et al. Mechanism of Mahuang Lianqiao Chixiaodou Decoction in treating eczema by network pharmacology and molecular docking technology[J]. China Journal of Chinese Materia Medica,2021,46(04):894-901.
DENG Zhengting, ZHAO Fan, ZHAO Tong, et al. Analysis on Medication Regularity of Traditional Chinese Medicine in Treatment of Intermediate and Advanced Non-small Cell Lung Cancer Based on Data Mining. [J]. Chinese Journal of Experimental Traditional Medical Formulae, 2022,28(3):171-179.
ZHOU Mei, KOU Yan, WANG Hongli. Effect of Modified Shengxian Decoction Combined with TP Chemotherapy on Non-Small Cell Lung Cancer and Its Influence on Inflammatory Cytokines and Immune Function. [J]. Liaoning Journal of Traditional Chinese Medicine, 2022,49(6): 84-87.
Lu J, Li J, Lin Z,et al. Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer. Cancer Lett. 2023 Jun 28;564:216205.
Blakely CM, Watkins TBK, Wu W, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet al. 2017 Dec;49(12):1693-1704.
Zheng Q, Dong H, Mo J, et al. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 2021 Jan 1;11(2):824-840.
Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non‐small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004; 25: 2053–9.
Tan AC. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer. 2020 Mar;11(3):511-518.
Moes-Sosnowska J, Szpechcinski A, Chorostowska - Wynimko J. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update. Tumour Biol. 2024;46(s1):S309-S325.
E. D. Kramer, S. L. et al. Abrams β-Catenin signaling in alveolar macrophages enhances lung metastasis through a TNF-dependent mechanism JCI Insight, 8 (8) (2023), 10. 1172.
Katoh M. Multilayered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/βcatenin signaling activation (Review). Int J Mol Med. 2018 Aug; 42(2): 713-725.
Y Liao, J Feng, W Sun, et al. CIRP promotes the progression of non-small cell lung cancer through activation of Wnt/β-catenin signaling via CTNNB1. J. Exp. Clin. Cancer Res., 40 (1) (2021), p. 275
Green DR. Apoptotic Pathways: Ten Minutes to Dead. Cell. 2005; 121: 671–674.
Lindner AU, Concannon CG, Boukes GJ, et al. Systems analysis of BCL2 protein family interactions establishes a model to predict responses to chemotherapy. Cancer Res. 2013; 73: 519–528.
Liu X, Shao Y, Zhang X, et al. Calycosin attenuates pulmonary fibrosis by the epithelial-mesenchymal transition repression upon inhibiting the AKT/GSK3β/β-catenin signaling pathway. Acta Histochem. 2021 Jul;123(5):151746.
Carpten JD, Faber AL, Horn C, et al. A Transforming Mutation in the Pleckstrin Homology Domain of AKT1 in Cancer. Nature. 2007; 448: 439–444.
Landgraf KE, Pilling C, Falke JJ, et al. Molecular Mechanism of an Oncogenic Mutation That Alters Membrane Targeting: Glu17Lys Modifies the PIP Lipid Specificity of the AKT1 PH Domain. Biochemistry. 2008; 47: 12260–12269.
Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. J Thorac Oncol. 2021 Feb;16(2):205-215.
Losuwannarak N, Maiuthed A, Kitkumthorn N, et al. Gigantol targets cancer stem cells and destabilizes tumors via the suppression of the PI3K/AKT and JAK/STAT pathways in ectopic lung cancer xenografts. Cancers. 2019; 11: 2032.
Liu F, Gao S, Yang Y, et al. Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway. Oncol. Rep. 2018; 39: 1523–1531.
Dimri M, Humphries A, Laknaur A, et al. NAD (P) H quinone dehydrogenase 1 ablation inhibits activation of the phosphoinositide 3-kinase/Akt serine/threonine kinase and mitogen-activated protein kinase / extracellular signal-regulated kinase pathways and blocks metabolic adaptation in hepatocellular carcinoma. Hepatology. 2020; 71: 549–568.
Chen T, Zhang P, Cong XF, et al. Synergistic antitumor activity of baicalein combined with lmonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway. Front Pharmacol. 2024 Jul 31;15:1405521.
Lindner AU, Concannon CG, Boukes GJ, et al. Systems analysis of BCL2 protein family interactions establishes a model to predict responses to chemotherapy. Cancer Res. 2013;73:519–528.
E. D. Kramer, S. L. et al. Abrams β-Catenin signaling in alveolar macrophages enhances lung metastasis through a TNF-dependent mechanism JCI Insight, 8 (8) (2023), 10. 1172.
Katoh M. Multilayered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/βcatenin signaling activation (Review). Int J Mol Med. 2018 Aug;42(2):713-725.
GUO Xiaofei, ZHANG Ping, BAI Jianqi, et al. Molecular Mechanism of Guben Jiedu Prescription in Regulating Immune Microenvironment of Lung Adenocarcinoma and Experimental Verification[J]. World Chinese Medicine, 2023, 18 (20): 2865-2871+2877.
LIU Huanyu, WANG Yanbing, YANG Tao, et al. Potential Action Mechanism of Qijia Fuzheng Formula in the Treatment of Cancer Related Fatigue of Lung Adenocarcinoma Based on Network Pharmacology and Molecular Docking [J]. World Chinese Medicine, 2021, 16 (11): 1685-1691.
Schraml P, Bendik I, Ludwig CU. Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and non-small cell lung carcinoma. Cancer Res. 1997;57(Sep (17)):3669–71.
Stav D, Bar I, Sandbank J. Usefulness of CDK5RAP3, CCNB2, and RAGE genes for the diagnosis of lung adenocarcinoma. Int J Biol Markers. 2007;22(Apr–Jun (2)):108–13. doi: 10. 1177/172460080702200204.
BI. Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signaling. Cancer Res. 2010;70(Jul (13)):5628–38.
Wang H, Li Y, Yu W, et al. Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer. Oncology letters. 2015;10(Jul (1)):51–60.
Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8(Aug (8)):816–24.
Diederichs S, Bulk E, Steffen B, et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res. 2004;64(Aug (16)):5564–9.
Rojas A, Figueroa H, Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis. 2010;31(Mar (3)):334–41.
Oczypok EA, Perkins TN, Oury TD. All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses. Paediatr Respir Rev. 2017 Jun; 23:40-49.
Bhat IA, Mir IR, Malik GH, et al. Comparative study of TNF-α and vitamin D reveals a significant role of TNF-α in NSCLC in an ethnically conserved vitamin D deficient population. Cytokine. 2022 Dec;160:156039.
Huyghe J, Priem D, Bertrand MJM. Cell death checkpoints in the TNF pathway. Trends Immunol. 2023 Aug;44(8):628-643.
ZHU Lingling, ZHANG Yani, SHI Tingting, et al. The role of tumor necrosis factor-α in the development of hepatocellular carcinoma[J]. Journal of Clinical Hepatology,2024,40(11):2320-2325.
SHI Huimin, SU Jie, LIU Huijin. Effects of TNF-αon the Biological Behavior of Lung Cancer Cells by Regulating NF-κB/PXR Inflammatory Pathway and Its Mechanism [J]. The Practical Journal of Cancer, 2024, 39(08): 1219-1223.
79Wang C, Wen M, Xu J, et al. GTSE1 promotes the growth of NSCLC by regulating microtubule-associated proteins through the ERK/MAPK pathway. Thorac Cancer. 2023 Jun;14(17):1624-1634. doi: 10. 1111/1759-7714. 14908. Epub 2023 Apr 20.
Xiong Ying, Shen Jingqiao, Liu Xianguo, et al. Effects of magnesium -L- threonate on migration and invasion ability and NF-κB/TNF-alpha signaling pathway of non -small cell lung cancer H460 cells[J]. Journal of Modern Oncology, 2024, 32(24): 4580-4587.
Chang W. T, Lai TH, Chyan YJ, et al. Specific medicinal plant polysaccharides effectively enhance the potency of a DC-based vaccine against mouse mammary tumor metastasis. PloS One. 2015;10
Farrag M, Ibrahim E, Abdelwahab H, et al. PDL-1 expression in lung carcinoma and its correlation with clinicopathological and prognostic characteristics. J Immunoassay Immunochem. 2021 Nov 2; 42(6): 679-690.
Ke M, Zhang Z, Xu B, et al. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells. Int Immunopharmacol. 2019;75:105824.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Yali Chen, Yuanchun Wang, Yuxian Wang, Jiejie Li, Peihua Shen
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
